Nautilus Biotechnology (NAUT) Equity Average (2020 - 2026)

Nautilus Biotechnology has disclosed Equity Average across 7 years of filings, most recently posting $150.7 million for Q1 2026.

• Equity Average for Q1 2026 came in at $150.7 million, down 25.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $150.7 million (down 25.24% YoY), and the FY2025 annual result was $182.9 million, down 22.86% from the prior year.
• Equity Average came in at $150.7 million for Q1 2026 at Nautilus Biotechnology, down from $163.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $356.6 million in Q1 2022 to a low of $150.7 million in Q1 2026.
• The 5-year median for Equity Average is $257.4 million (2024), against an average of $255.1 million.
• Across the five-year window, Equity Average jumped 1172.35% in 2022 and retreated 25.24% in 2026, its largest moves.
• Nautilus Biotechnology's Equity Average stood at $320.1 million in 2022, then declined by 15.25% to $271.3 million in 2023, then declined by 20.36% to $216.1 million in 2024, then slipped by 24.54% to $163.1 million in 2025, then dropped by 7.58% to $150.7 million in 2026.
• The last three Equity Average figures came in at $150.7 million (Q1 2026), $163.1 million (Q4 2025), and $175.1 million (Q3 2025), per Business Quant data.